BioCryst Pharmaceuticals, Inc. Common Stock Earnings Dividend

BioCryst Pharmaceuticals, Inc. Common Stock’s revenue jumped 33.61% since last year same period to $218.25Mn in the Q2 2026. On a quarterly growth basis, BioCryst Pharmaceuticals, Inc. Common Stock has generated 39.53% jump in its revenue since last 3-months.

BioCryst Pharmaceuticals, Inc. Common Stock’s net profit jumped 1441.69% since last year same period to $78.4Mn in the Q2 2026. On a quarterly growth basis, BioCryst Pharmaceuticals, Inc. Common Stock has generated 110.86% jump in its net profits since last 3-months.

BioCryst Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 1053.91% since last year same period to 35.92% in the Q2 2026. On a quarterly growth basis, BioCryst Pharmaceuticals, Inc. Common Stock has generated 107.78% jump in its net profit margins since last 3-months.

BioCryst Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.1 - a -28.57% fall from last quarter’s estimates.

BioCryst Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.1.

BioCryst Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 650% since last year same period to 0.3 in the Q2 2026. This indicates that the BioCryst Pharmaceuticals, Inc. Common Stock has generated 650% annual rate of jump in its earning per share (EPS) in the last 4 quarters.